New Drugs

Antiarrhythmic drugs

W S HILLS, B WHITING

Most patients with cardiac arrhythmias require treatment with antiarrhythmic drugs, although recent advances in surgical and electrical techniques are promising.

The ideal antiarrhythmic compound should have:
(1) A wide range of therapeutic activity in both atrial and ventricular arrhythmias.
(2) Parenteral and oral formulations to permit simple dosage schedules.
(3) Pharmacokinetic properties that permit long term prophylactic treatment.
(4) Lack of serious cardiac depressant activity or non-cardiac side effects.

Although the ideal agent has not yet been found, many drugs are now under investigation. Here we review the drugs in current clinical use and refer to other compounds at present under investigation.

The recent development of rapid analytical methods to measure concentrations of antiarrhythmic drugs has allowed therapeutic drug monitoring to play an increasing part in this relatively difficult therapeutic area. Monitoring of drug concentrations is particularly important as the clinical circumstances surrounding cardiac arrhythmias may lead to considerable intersubject and intrasubject differences in pharmacokinetic variables. Variations in absorption, clearance, and volume of distribution may lead to pronounced differences in dose-concentration relations. The plasma concentrations associated with safe and effective antiarrhythmic treatment are usually confined to a narrow range, and this necessitates careful titration of the dose. In addition, efficacy is often difficult to determine if the arrhythmia, although potentially serious, occurs infrequently. The best approach to antiarrhythmic treatment now entails this achievement of target plasma concentrations known to be associated with successful suppression of arrhythmias by dosage adjustments dictated by both concentration monitoring and clinical observation.

Classification of antiarrhythmic agents

Compounds with antiarrhythmic activity show great variation in their chemical structure and have been classified according to:
(1) their anatomical site of action (table I); (2) their clinical range of activity; and (3) their electrophysiological action on isolated cardiac fibres (Vaughan Williams, 1970) (table II).

This third classification allows drugs to be characterised at the preclinical phase of development, but it is of limited clinical value and excludes some agents with antiarrhythmic activity, such as the cardiac glycosides. Four types of basic activity are recognised;

---

**Table I**—Site of action of antiarrhythmic compounds

<table>
<thead>
<tr>
<th>Sinus node, atrium:</th>
<th>Anomalous pathway:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beta-adrenoceptor blocking agents</td>
<td>Disopyramide</td>
</tr>
<tr>
<td>Digoxin</td>
<td>Amiodarone</td>
</tr>
<tr>
<td>Verapamil</td>
<td>Procainamide</td>
</tr>
<tr>
<td>Quinidine</td>
<td>Quinidine</td>
</tr>
<tr>
<td>Disopyramide</td>
<td>Disopyramide</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>Venticline</td>
</tr>
<tr>
<td>Quinidine</td>
<td>Lignocaine</td>
</tr>
<tr>
<td>Atrioventricular node:</td>
<td>Disopyramide</td>
</tr>
<tr>
<td>Digoxin</td>
<td>Tocainide</td>
</tr>
<tr>
<td>Verapamil</td>
<td>Tocainide</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>Phenytoin</td>
</tr>
<tr>
<td></td>
<td>Procainamide</td>
</tr>
<tr>
<td></td>
<td>Quinidine</td>
</tr>
<tr>
<td></td>
<td>Amiodarone</td>
</tr>
</tbody>
</table>

**Table II**—Classification (Vaughan-Williams) of antiarrhythmic drugs

<table>
<thead>
<tr>
<th>Class I</th>
<th>Class II</th>
<th>Class III</th>
<th>Class IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Quinidine</td>
<td>Beta-adrenoceptor blocking compounds</td>
<td>Amiodarone Verapamil</td>
</tr>
<tr>
<td></td>
<td>Procainamide</td>
<td>Disopyramide Bretyllium</td>
<td>Disopyramide Sotalol</td>
</tr>
<tr>
<td></td>
<td>Disopyramide Bretyllium</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lignocaine</td>
<td></td>
</tr>
<tr>
<td>H</td>
<td>Aprindine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Metinaline</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lorcainide</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Flecaainide</td>
</tr>
</tbody>
</table>

future developmental agents may require recognition of further classes. In addition, some drugs may have more than one action. Therapeutic success, however, is usually associated with one dominant action.

Class I agents contain drugs with local anaesthetic properties that have membrane stabilising activity. Depolarisation of the cardiac cell membrane is depressed by restricting entry of the fast sodium current (see fig 2 in article on calcium antagonists, 2 April, p 1127). This reduces the maximum rate of rise of phase 0 of the action potential and depresses the rate of phase 4 diastolic depolarisation. These effects tend to reduce spontaneous automaticity. These agents may be further subdivided according to their influence on the duration of the action potential, which may lengthen (group IA), shorten (group IB), or be unaffected (group IC).

Class II agents reduce the potential for arrhythmias to develop in response to catecholamines. Bretyllium, for example, blocks the release of sympathetic transmitters. The beta-adrenoceptor antagonists act as competitive antagonists and also block the possible arrhythmogenic effect of cyclic adenosine-5'-monophosphate.

Class III agents prolong the duration of the action potential with resulting prolongation of the effective refractory period.

Class IV agents inhibit the slow inward calcium mediated current and depress phase 2 and phase 3 of the action potential. These actions have an important influence on the upper and middle parts of the atrioventricular node, and these effects may have particular value in blocking one limb of a re-entry circuit.
Class I agents

**Quinidine**

Quinidine is the parent compound of the class I antiarrhythmic drugs.

**Mechanism of action**

Quinidine reduces the maximal rate of depolarisation, depresses spontaneous and failure the progressive and lar, parenteral adequate is arrhythmias occur effects may however, (seven diarrhoea) may arrest, fever, with (see Table V).

**Pharmacokinetics**

About 70% of an oral dose is absorbed from the gut. Peak effects occur within one to three hours. The half-life is relatively short (seven hours), and slow release preparations (table III) are now available. The bioavailability of these preparations, however, may be lower than that of non-sustained release products. Antiarrhythmic effects on atrial and ventricular arrhythmias are seen with drug concentrations of 2-5 mg/L. Quinidine is highly protein bound (80-90%) and is metabolised by hydroxylation. In liver disease the clearance is reduced; half life is increased, protein binding is reduced, and lower total plasma concentrations may be effective. In congestive heart failure the half life is not affected. Quinidine interacts with digoxin and may precipitate digoxin toxicity. The dose of cardiac glycoside accordingly needs to be reduced.

**Clinical use**

Quinidine is now of limited clinical use. The lack of an adequate parenteral formulation restricts its use to prophyaxis after cardioversion or after acute administration of lignocaine. It is active against both atrial and ventricular arrhythmias.

**Pharmacokinetics**

About 70% of an oral dose is absorbed from the gut. Peak effects occur within one to three hours. The half-life is relatively short (seven hours), and slow release preparations (table III) are now available. The bioavailability of these preparations, however, may be lower than that of non-sustained release products. Antiarrhythmic effects on atrial and ventricular arrhythmias are seen with drug concentrations of 2-5 mg/L. Quinidine is highly protein bound (80-90%) and is metabolised by hydroxylation. In liver disease the clearance is reduced; half life is increased, protein binding is reduced, and lower total plasma concentrations may be effective. In congestive heart failure the half life is not affected. Quinidine interacts with digoxin and may precipitate digoxin toxicity. The dose of cardiac glycoside accordingly needs to be reduced.

### Table III—Choice of drugs used in treatment of supraventricular arrhythmias

<table>
<thead>
<tr>
<th>Drug (proprietary name)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verapamil (Cardioxil)</td>
<td>5-10 mg intravenous bolus over 30 s. Intravenous infusion 5-10 mg/h. Total dose 25-100 mg daily. Oral dose 40-120 mg thrice daily</td>
</tr>
<tr>
<td>Beta-blockers:</td>
<td></td>
</tr>
<tr>
<td>Propranolol (Inderal)</td>
<td>5 mg intravenous bolus may be repeated until 20-25 mg given</td>
</tr>
<tr>
<td>Metoprolol (Betaxolol, Lopressor)</td>
<td>5 mg intravenous bolus may be repeated until 5 mg given</td>
</tr>
<tr>
<td>Others:</td>
<td></td>
</tr>
<tr>
<td>Digoxin (Lanoxin)</td>
<td>0.25-0.75 mg intravenously, then maintenance oral dose of 0.25 mg daily. Avoid in Wolf-Parkinson-White syndrome</td>
</tr>
<tr>
<td>Disopyramide (Rhythmodan, Norpace; slow release—Rhythmodan Retard, Dirhythm SA)</td>
<td>2 mg/kg up to 150 mg over 5 minutes. Repeat if necessary. Maintenance infusion 20-30 mg/h up to 800 mg daily. Oral dose 300-800 mg daily.</td>
</tr>
<tr>
<td>Amiodarone (Cordarone X)</td>
<td>3.5 mg intravenously over 5 minutes. Oral dose 200 thrice daily for first week then 200 mg daily.</td>
</tr>
<tr>
<td>Procainamide (Proventyl; slow release—Procainamide Durules)</td>
<td>100 mg intravenous bolus repeated up to 1 g in one hour—maintenance 2-6 mg/min. Oral dose 250 mg every 4-6 hours or durules 1-2 g every 8 hours</td>
</tr>
<tr>
<td>Quinidine (Quinidinard; slow release—Kudinard, Kinidin Durules)</td>
<td>Oral dose 200-400 mg 3-4 times daily or slow release 500 mg every 12 hours</td>
</tr>
</tbody>
</table>

### Table IV—Choice of antiarrhythmic drugs for ventricular arrhythmias

<table>
<thead>
<tr>
<th>Drug (proprietary name)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lignocaine (Xylocard, Lidothesin)</td>
<td>50-100 mg intravenous bolus; infusion 1-4 mg/min. Half dose in hepatic and cardiac failure (see text)</td>
</tr>
<tr>
<td>Mexiletine (Mexitil)</td>
<td>100-250 mg over 5-10 minutes followed by infusion of 250 mg over 1 hour, 250 mg over 2 hours, then 0.5 mg/min. Oral dose 200-300 mg every 8 hours</td>
</tr>
<tr>
<td>Disopyramide (Tocainide (Tonocard)</td>
<td>0.5-0.75 mg/kg/min for 15 minutes. Oral dose 400-800 mg then 400 mg every 8 hours</td>
</tr>
<tr>
<td>Procainamide (Epanutin)</td>
<td>See Table III</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>90-100 mg intravenously over 5 minutes, repeat to 1 g. Oral dose 1 g then 500 mg for two days, then 400 mg daily.</td>
</tr>
<tr>
<td>Quinidine (Bretynyl tosylate (Bretylac)</td>
<td>5 mg/kg intramuscularly repeated every 6-8 hours at varying sites to avoid minor necrosis</td>
</tr>
</tbody>
</table>

### Adverse effects

**Cardiac**—Myocardial depression occurs at high plasma concentrations with associated vasodilatation and hypotension. Sinus arrest, sinoatrial block, atrioventricular dissociation, and progressive QRS and QT prolongation may occur. QT prolongation may facilitate the development of re-entry arrhythmias.

Other—Gastrointestinal effects (nausea, vomiting, and diarrhoea) may occur. Cinchonism and hypersensitivity reactions with fever, purpura, thrombocytopenia, and hepatic dysfunction may also occur.

**Procainamide**

Procainamide exhibits similar electrophysiological properties to those described for quinidine.

**Clinical use**

Procainamide is available for both parenteral and oral use and can be effective in the treatment of atrial, junctional, and ventricular arrhythmias. The standard intravenous dose is 100 mg every two minutes, repeating this to a total of 1000 mg over the first hour. Oral treatment may be given as prophylactic therapy.
DISOPYRAMIDE

The electrophysiological properties of disopyramide are similar to those of quinidine.

Clinical use

Both parenteral and oral preparations are available. The range of activity includes action against both atrial and ventricular arrhythmias, including supraventricular tachycardia and ventricular extrasystoles.

Pharmacokinetics

Disopyramide is commercially available as both the base compound and the phosphate salt. Bioavailability is about 70-80%. The half life in normal subjects is six to eight hours. The main metabolite is the N-dealkylated form of disopyramide. This is excreted by the kidneys, as is most of the parent compound. The dose should be reduced in severe renal failure. The therapeutic range is 2-5 mg/l.

Adverse effects

Cardiac—Myocardial depression may be clinically important and is related both to the plasma concentration and to the rate of administration of the compound. Use of the drug is therefore contraindicated in heart failure or severe left ventricular dysfunction. QT prolongation related to the drug concentration may also occur, and this may predispose to ventricular arrhythmias with a re-entry mechanism. Sinus node depression may also occur. Other—Disopyramide has anticholinergic activity, and urinary retention, dry mouth, and blurred vision often occur. Glaucoma may also be precipitated.

LIGNOCaine

Lignocaine has typical class I electrophysiological effects.

Clinical use

Lignocaine remains the first line drug in the treatment of ventricular arrhythmias after acute myocardial infarction and cardiac surgery. After intravenous administration long term treatment is continued with an alternative class I antiarrhythmic given by mouth. After intramuscular injection absorption is erratic, and blood concentrations achieved vary widely according to the haemodynamic state of the patient.

Pharmacokinetics

Lignocaine is hydrolysed in the gastrointestinal tract and is subject to extensive first pass metabolism in the liver. Adequate blood concentrations are therefore not obtained after oral administration. After intravenous administration the elimination half life is about two hours. Clearance is related to the hepatic blood flow and hepatic function. Clearance is prolonged in the elderly, in cardiac failure, and in hepatic disease, and infusion rates require appropriate adjustment in these cases. Therapeutic efficacy is associated with blood concentrations in the range 1-5-5-0 mg/l. Toxicity may occur at a wide range of total blood concentrations and may show considerable overlap with the therapeutic range. The degree of toxicity, however, correlates better with the free drug concentration than with the total plasma concentration. Protein binding may be important in many clinical conditions. The fraction of drug that is free in the plasma may vary from 20% to 40% and is determined largely by the concentration of acute phase proteins, notably α-1 acid glycoprotein. After myocardial infarction long term infusion leads to progressively increasing plasma concentrations, and a true steady state may not be achieved. Although this may be related to diminished plasma clearance, it may also reflect increasing concentrations of α-1 acid glycoprotein. In these patients although total lignocaine concentrations are raised, the free drug concentrations may remain relatively constant. The precise relation between the total and free concentrations of lignocaine and antiarrhythmic activity remains to be clarified.

MEXILETINE

Mexiletine is a primary amine with similar electrophysiological actions to those of lignocaine.

Clinical use

Mexiletine is effective after intravenous and oral administration in the treatment of ventricular arrhythmias.

Pharmacokinetics

Peak plasma concentrations are obtained two to four hours after oral administration. Mexiletine is extensively metabolised. The half life is nine to 12 hours in normal volunteers and is prolonged in patients with cardiac disease, particularly those who have sustained an acute myocardial infarction (up to 26 hours). Administration of narcotic analgesics may be associated with reduced absorption. About 10-20% of an administered dose is excreted unchanged in the urine at normal urinary pH, but renal clearance depends on urinary pH and may be reduced when the urine is alkalinised by antacids. Effective plasma concentrations lie in the range of 0-75-2-0 mg/l.

Adverse effects

Cardiac adverse effects include hypotension, bradycardia, and transient atrioventricular block. Other—Neurological side effects are common and include tremor, nystagmus, diplopia, dizziness, dysarthria, paraesthesiae, ataxia, and confusion.

TOCAINE

Toxainde is a primary amine with similar electrophysiological and antiarrhythmic properties to those of lignocaine.

Clinical use

Toxainde is active after both intravenous and oral administration and may be used to treat acute and chronic ventricular arrhythmias.
Pharmacokinetics

Almost all of the tocainide in an oral preparation is absorbed from the gut, and peak plasma concentrations are achieved within 60-90 minutes of ingestion. The elimination half life is around 11-15 hours. Plasma protein binding is about 50%. At least 40% of the drug is excreted unchanged in the urine, and the remainder is excreted by hepatic metabolism. Some 25% is excreted as N-carboxy tocainide; other metabolites include glucuronide and lactoyxilide salts, which are inactive. Hepatic clearance is low, which suggests that a substantial first pass effect is unlikely. Antiarrhythmic activity occurs within the plasma concentration range of 6-12 mg/l.

Adverse effects

Cardiac—No appreciable adverse haemodynamic effects occur at plasma concentrations within the therapeutic range.

Other—Gastrointestinal side effects include anorexia, nausea, vomiting, constipation, and abdominal pain. Effects in the central nervous system are similar to those associated with mexiletine and appear to be related to peak plasma drug concentrations. Rash, and interstitial pulmonary alveolitis have occasionally necessitated withdrawal of the drug.

Investigational agents

APRINDINE

Mechanism of action

Aprindine is a class I antiarrhythmic compound with local anaesthetic activity. Electrophysiological studies show slowing of conduction through the bundle of His with QRS prolongation and increases in the refractory periods of the atria, ventricles, and atrioventricular node.

Clinical use

Aprindine is effective in both ventricular and supraventricular arrhythmias, but full antiarrhythmic activity may take several days to develop.

Pharmacokinetics

Aprindine is effective after both oral and intravenous administration: oral bioavailability is high. Relatively long, albeit variable half lives have been reported, of about 22 hours (range 12-66). Protein binding is relatively high at 85-95%. Metabolism occurs by hydroxylation and subsequent glucuronidation. The therapeutic ratio is small. Therapeutic activity occurs within plasma concentrations of 1-3 mg/l, but side effects occur often at concentrations above 2 mg/l.

Adverse effects

Central nervous system side effects are common, including tremor. Gastrointestinal side effects are less common, and idiosyncratic reactions may affect the liver or bone marrow with cholestasis and agranulocytosis respectively.

LORCAINIDE

Mechanism of action

Lorcainide is a class I antiarrhythmic compound with local anaesthetic activity. It seems to be effective in suppressing ventricular ectopic activity.

Pharmacokinetics

Lorcainide shows a large first pass effect that is apparently dose dependent: bioavailability increases from 4% with a small single dose to 60%, with a relatively large, 200 mg, dose. Its primary metabolite, N-dealkylated lorcainide or norlorcainide, has antiarrhythmic activity and a prolonged half life. Side effects include heart block, hypotension, and insomnia.

FLECAINIDE

Mechanism of action

Flecainide is similar in activity to lorcainide. Preliminary studies suggest that it is effective in suppressing ventricular arrhythmias.

Pharmacokinetics

The elimination half life is between 15 and 20 hours. Note: These drugs require further evaluation before their full clinical value can be assessed, and they remain as investigational agents.

Class II

BETA-ADRENOCEPTOR BLOCKING COMPOUNDS

New beta-adrenoceptor blocking compounds in class II continue to be produced in large numbers. Their antiarrhythmic range is identical despite different properties in regard to cardioselectivity, partial agonist activity, and potency of membrane stabilising activity. The newer drugs in this group will be reviewed in a separate article.

Mechanism of action

Catecholamine augmented phase 4 depolarisation is blocked. The action potential is shortened, and the functional refractory period of the atrioventricular node is prolonged.

Clinical use

Beta-adrenoceptor blocking drugs may be used when arrhythmias are associated with high levels of catecholamine production, including arrhythmias induced during anaesthesia. Their long term use in secondary prevention trials after acute myocardial infarction has been extensively reviewed. While propranolol remains the reference compound, most agents in class II may be given intravenously or by mouth. Practolol given intravenously has been generally used as the first line drug to reduce the ventricular rate in atrial flutter and atrial fibrillation or to cardiovert paroxysmal atrial tachycardia. Long term management has then required the use of alternative agents. Metoprolol and atenolol are increasing in their popularity. Sotalol has additional mild class III activity and may show a wider range of activity.

Adverse effects

Cardiac—Myocardial depression with hypotension or cardiac failure may occur in patients with little cardiac reserve. Fewer haemodynamic effects may occur with agents with partial agonist activity.

Other—Increased airways obstruction and reduction of peripheral arterial blood flow may occur secondary to blockade of
beta₂-receptors by non-selective agents. Beta-blocking agents are therefore contraindicated in patients with obstructive airways or peripheral vascular disease.

**Class III**

**AMIODARONE**

**Mechanism of action**

Amiodarone prolongs the duration of the action potential and the effective refractory period in both the atria and ventricles. In higher dosage it may have beta-receptor inhibitory activity and effects such as those with quinidine.

**Clinical use**

The full therapeutic range is not yet known. Excellent results have been reported with both supraventricular and ventricular arrhythmias, particularly if associated with the Wolff-Parkinson-White syndrome, and resistant ventricular arrhythmias. Present use is limited to patients whose arrhythmias are resistant to standard antiarrhythmic compounds.

**Pharmacokinetics**

Antiarrhythmic activity is evident after some four to six days of oral treatment. The elimination half life is long (30-45 days) and antiarrhythmic activity may continue for several months after treatment is stopped. Antiarrhythmic efficacy after intravenous administration is variable in its onset, occasionally occurring immediately: this activity does not appear to bear a simple relation to plasma concentration. The amiodarone molecule is deiodinated and blocks the peripheral conversion of thyroxine to triiodothyronine. It leads to a consistent rise in serum reverse triiodothyronine concentrations, and early studies suggest that these concentrations may reflect the efficacy and toxicity of amiodarone.

**Adverse effects**

*Cardiac*—Haemodynamic effects after intravenous administration are usually unimportant, but vasodilatation may occur leading to hypotension. Bradycardia may also occur.

*Other*—These are common and include corneal micro deposits of yellow brown granules (universal), photosensitisation, skin discoloration with grey or bluish pigmentation, hypothyroidism or hyperthyroidism (2-3% of patients), rise in hepatic enzyme concentrations, interstitial pulmonary infiltration, and proximal muscle weakness. These adverse effects are usually reversed when the drug is withdrawn, but serial eye examinations are recommended during long term use.

**Class IV**

**VERAPAMIL**

**Mechanism of action**

Verapamil inhibits slow inward calcium mediated current and is the only agent of this class at present available. The other calcium channel blockers will be reviewed separately in this series.

**Clinical use**

The major action of verapamil is exerted on conduction through the atrioventricular node. The ventricular response in atrial fibrillation and flutter is controlled, and cardioversion of paroxysmal re-entrant atrioventricular nodal tachycardia is often achieved. Verapamil is the drug of first choice in paroxysmal supraventricular tachycardia.

**Pharmacokinetics**

Verapamil is active when given intravenously or by mouth.

The elimination half life is three to seven hours. This is prolonged in patients with liver disease; the volume of distribution is increased and clearance diminished. Although absorption from the gastrointestinal tract is almost complete, a major first pass effect is the liver reducing systemic bioavailability to under 25%. Renal excretion accounts for 70%, of an oral dose. Norverapamil, an active metabolite, is formed during hepatic metabolism.

**Adverse effects**

*Cardiac*—Myocardial depression may occur in patients with cardiac failure. Drug interactions may occur with beta-adrenoceptor blocking drugs and with digoxin. Concomitant intravenous treatment with beta-blockers should be avoided, and verapamil should be avoided in patients with the sick sinus syndrome or atrioventricular node disease.

*Other*—Nausea, vomiting, and hypotension may rarely occur.

**Bibliography**


Background review of drug monitoring of antiarrhythmics.


Emphasises the relation of QT interval to plasma concentrations of disopyramide.


This paper shows atrial and ventricular activity of quinidine.


Standard reference for accepted therapeutic range of lidocaine.


Review of clinical studies and detailed pharmacology of new antiarrhythmics.


Standard reference for efficacy of procainamide and toxicity related plasma concentrations.


Interesting use of biochemical marker of activity.


Review of new antiarrhythmics.


Review of activity of amiodarone.


